CSC Sees Q4 Adjusted EPS of $0.19-0.21

CSC (NYSE: CSC) today provided a preliminary and unaudited update for the fourth quarter and the full fiscal year 2012, ended March 30, 2012.

On December 27, 2011, the Company announced a material impairment of its net investment in the UK National Health Service (NHS) contract and at the same time, withdrew its guidance for its fiscal year 2012. Given the uncertainty surrounding the future of the NHS contract, the Company was not in a position to reasonably estimate fiscal 2012 financial performance.

The preliminary and unaudited Q4 update is as follows:

Revenue: $4.1B

Adjusted EPS $0.19-0.21

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.